Nureca Q1 Results FY27: Net Profit Soars 277% to Rs 3 Crore as Revenue Grows 18%

July 22, 2026
Posted by: Ankit Jaiswal
Category: News

Nureca Q1 FY27: consolidated PAT Rs 3 Cr, up 277% YoY. Revenue Rs 40 Cr, up 18%. Gross profit swings to Rs 2 Cr from a loss of Rs 1 Cr. Shares up 9.69% as of 22 July 2026.

Nureca Q1 results FY27 were announced on Tuesday, 21 July 2026, with the company reporting the numbers summarised below on a consolidated basis for the quarter ended 30 June 2026.

Shares of Nureca were trading up 10.58 at Rs 323.10 on the NSE as of Wednesday, 22 July 2026. The healthcare and wellness products company, known for the Dr Trust brand, delivered a sharp profitability turnaround alongside healthy revenue growth.

Click Here – Get Free Investment Predictions

Table of Contents

Nureca Q1 Results FY27 Key Takeaways

Here are the most important numbers from the June 2026 quarter at a glance.

Revenue: Rs 40 Cr in Q1 FY27 versus Rs 34 Cr in Q1 FY26, up 18% year on year.
Gross Profit: Rs 2 Cr in Q1 FY27, a turnaround from a loss of Rs 1 crore in Q1 FY26.
Net Profit (PAT): Rs 3 Cr in Q1 FY27 versus Rs 0.81 Cr in Q1 FY26, up 277% year on year.
Nureca shares were trading up 10.58 at Rs 323.10 as of Wednesday, 22 July 2026.

Nureca Q1 Results FY27 Financial Highlights

The table below summarises the consolidated numbers reported in the Nureca Q1 results FY27 against the year ago quarter.

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 40 Cr	Rs 34 Cr	+18%
Gross Profit	Rs 2 Cr	-Rs 1 Cr (loss)	Turnaround
Net Profit (PAT)	Rs 3 Cr	Rs 0.81 Cr	+277%

All figures are on a consolidated basis as reported for the quarter ended 30 June 2026.

Nureca Q1 Results FY27 Performance Analysis

Get Personalised Guidance from a SEBI-Registered Investment Advisor

The Nureca Q1 results FY27 show a clean margin recovery story. Gross profit swung from a loss of Rs 1 crore to a profit of Rs 2 crore, and net profit nearly quadrupled to Rs 3 crore from Rs 0.81 crore, both on a comparatively modest 18% revenue increase, confirming the improvement is driven by margin recovery rather than volume alone.

For a consumer healthcare products company, moving from a gross loss to a gross profit in the Nureca Q1 results FY27 likely reflects better product mix, improved input cost management, or reduced discounting, all of which are more sustainable drivers of profitability than one-off items.

The strong 10.58% stock rally reflects the market rewarding both the scale of the turnaround and the fact that it came alongside genuine revenue growth rather than cost cutting on a shrinking base.

Nureca Q1 Results FY27: Key Business Factors

1. Gross Margin Turnaround

The swing from a gross loss to a gross profit in the Nureca Q1 results FY27 is the core positive signal, indicating the fundamental unit economics of the business have improved.

2. Profit Growth Alongside Revenue Growth

Unlike a pure cost cutting story, the profit recovery came with 18% revenue growth, suggesting the improvement is compatible with continued business expansion.

3. Small Base Effect on Percentage Growth

With PAT growing from a very small Rs 0.81 crore base, the 277% growth rate in the Nureca Q1 results FY27, while directionally very positive, should be read alongside the modest absolute profit figures.

Dividend Details

Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company’s official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.

Nureca Q1 Results FY27 Outlook for the Full Year

After the Nureca Q1 results FY27, the key question is whether the gross margin recovery can be sustained and built upon as the company scales revenue further. Repeat profitable quarters with continued margin improvement would confirm this is a durable turnaround rather than a single quarter’s gain.

Nureca Stock Performance After the Q1 Results

Download the Univest iOS App or Univest Android App to track Nureca live share price and upcoming quarterly results.

Nureca shares were trading up 10.58 at Rs 323.10 on the NSE as of Wednesday, 22 July 2026, a day after the Nureca Q1 results FY27 were announced.

Investors can compare the trend of the counter with the Nifty 500 index to judge how the stock is placed relative to the broader market after the June quarter results.

Key Risks

Investors going through the fine print of the Nureca Q1 results FY27 should also weigh the following risks.

1. Small Base and Scale

With absolute profit still small at Rs 3 crore, the Nureca Q1 results FY27 percentage growth figures can be volatile quarter to quarter, and investors should track the trend over several quarters.

2. Consumer Healthcare Competitive Intensity

The consumer wellness and healthcare products category has become increasingly competitive, which could pressure the margin gains if not managed carefully.

3. Durability of the Margin Recovery

A single quarter of margin improvement needs to be followed by further profitable quarters before it can be considered a structural shift rather than a temporary gain.

Conclusion

Nureca Q1 results FY27 show a strong turnaround with net profit up 277% at Rs 3 crore and gross profit swinging to positive, alongside 18% revenue growth, a combination the market rewarded with a 10.58% stock rally. Investors should track margin durability into the September quarter and consult a SEBI-registered advisor before acting on the numbers.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Nureca Q1 Results FY27

When were the Nureca Q1 results FY27 announced?

Ans. The Nureca Q1 results FY27 were announced on Tuesday, 21 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.

What is the PAT in the Nureca Q1 results FY27?

Ans. The consolidated PAT in the Nureca Q1 results FY27 stood at Rs 3 crore, up 277% from Rs 0.81 crore in Q1 FY26.

What was the revenue in the Nureca Q1 results FY27?

Ans. Revenue in the Nureca Q1 results FY27 stood at Rs 40 crore, up 18% from Rs 34 crore in Q1 FY26.

What happened to gross profit in the Nureca Q1 results FY27?

Ans. Gross profit in the Nureca Q1 results FY27 swung to Rs 2 crore from a loss of Rs 1 crore in Q1 FY26, a turnaround that underpinned the sharp net profit growth.

What does Nureca do?

Ans. The company sells healthcare and wellness products, including devices and equipment under the Dr Trust brand.

How is the stock trading after the Nureca Q1 results FY27?

Ans. Nureca shares were trading up 10.58% at Rs 323.10 on the NSE as of Wednesday, 22 July 2026, a day after the Nureca Q1 results FY27 were announced.

Is the stock a good buy after the Nureca Q1 results FY27?

Ans. The Nureca Q1 results FY27 show a genuine margin turnaround alongside revenue growth, though the small profit base means percentage figures can be volatile. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.

Where can I verify the Nureca Q1 results FY27?

Ans. The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.

Q1 Results FY27

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.